tiprankstipranks
Advertisement
Advertisement
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Outperforms and Non-Dilutive Financing Extends Runway; $10 Price Target Maintained
PremiumRatingsAutolus Therapeutics: Buy Rating Reiterated as Aucatzyl Outperforms and Non-Dilutive Financing Extends Runway; $10 Price Target Maintained
9d ago
Autolus Raises AUCATZYL Outlook, Secures New Credit Facility
Premium
Company Announcements
Autolus Raises AUCATZYL Outlook, Secures New Credit Facility
9d ago
Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M
Premium
The Fly
Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M
9d ago
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
PremiumRatingsAutolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
3M ago
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
Premium
Ratings
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
3M ago
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
Premium
The Fly
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
3M ago
Analyst Maintains Buy on Autolus, Reiterates $9 Price Target on Restructuring Savings and Clinical Catalysts
PremiumRatingsAnalyst Maintains Buy on Autolus, Reiterates $9 Price Target on Restructuring Savings and Clinical Catalysts
3M ago
Autolus Therapeutics Announces Workforce Reduction and Cost Restructuring
Premium
Company Announcements
Autolus Therapeutics Announces Workforce Reduction and Cost Restructuring
3M ago
Autolus Therapeutics to reduce workforce by approximately 13%
Premium
The Fly
Autolus Therapeutics to reduce workforce by approximately 13%
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100